on September 15, 2005
Published online before print September 15, 2005, doi: 10.1161/01.ATV.0000186365.73973.f0
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on March 17, 2005
Accepted on September 1, 2005
Dietary and Genetic Probes of Atherogenic Dyslipidemia
Ronald M. Krauss *
From Children’s Hospital Oakland Research Institute, Oakland, Calif.
* To whom correspondence should be addressed. E-mail: RKrauss{at}chori.org.
Abstract--A goal of dietary management of cardiovascular disease risk in patients with obesity and metabolic syndrome is improvement in the atherogenic dyslipidemia comprising elevated triglyceride, reduced high-density lipoprotein (HDL) cholesterol, and increased numbers of small, dense low-density lipoprotein (LDL) particles. Individuals with a genetically influenced trait characterized by a high proportion of small, dense LDL (phenotype B) respond to a low-fat, high-carbohydrate diet with greater reduction of LDL cholesterol, apoprotein B, and mid-sized LDL2 particles than unaffected subjects (phenotype A). In contrast, in phenotype A subjects there is a reciprocal shift from large LDL1 to small LDL3 such that a high proportion convert to phenotype B. There is evidence for heritable effects on these diet-induced subclass changes and for the involvement of specific genes. For example, a haplotype of the APOA5 gene associated with increased plasma triglyceride and small, dense LDL predicts greater diet-induced reduction of LDL2, a haplotype-specific effect that is strongly correlated with both increased VLDL precursors and LDL4 products. Understanding of such diet-genotype interactions may help to elucidate mechanisms that are responsible for phenotype B and for its differential dietary responsiveness. This information may also ultimately help in identifying those individuals who are most likely to achieve cardiovascular risk benefit from specific dietary interventions.
This article has been cited by other articles:
 |
|
 |
|
  Z. T. Bloomgarden Insulin Resistance, Dyslipidemia, and Cardiovascular Disease Diabetes Care, August 1, 2007; 30(8): 2164 - 2170. [Full Text] [PDF]
|
|
|
|
 |
|
 O. Ben-Yehuda High-Sensitivity C-Reactive Protein in Every Chart?: The Use of Biomarkers in Individual Patients J. Am. Coll. Cardiol., May 29, 2007; 49(21): 2139 - 2141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rizzo, R. Trepp, K. Berneis, and E. R Christ Atherogenic lipoprotein phenotype and low-density lipoprotein size and subclasses in patients with growth hormone deficiency before and after short-term replacement therapy Eur. J. Endocrinol., March 1, 2007; 156(3): 361 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Gillies and E. S. Krul Using Genetic Variation to Optimize Nutritional Preemption J. Nutr., January 1, 2007; 137(1): 270S - 274S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Griel, E. H. Ruder, and P. M. Kris-Etherton The Changing Roles of Dietary Carbohydrates: From Simple to Complex Arterioscler Thromb Vasc Biol, September 1, 2006; 26(9): 1958 - 1965. [Abstract] [Full Text] [PDF]
|
|